Recent studies suggest that treatment with RAS inhibitors, including KRASG12C inhibitors, SHP2 inhibitors, or MEK inhibitors, could trigger immune cells to effectively lift the immunosuppressive status and allow for ICI response in preclinical models of KRAS-mutant CRC [32, 76]. This evidence concerns the gene KRAS and colorectal carcinoma.